Spyre Therapeutics, Inc. (SYRE) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
025M50M75M100M125M150M175M200MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
0815223038455260Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Operating Expenses

Research And Development ExpensesGeneral And Administrative ExpensesOther Expenses
025M50M75M100M125M150M175M200MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
-90M-79M-67M-56M-45M-34M-22M-11M1Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EPS

Revenue Variation (%)

Revenue Variation
-200-175-150-125-100-74-49-241Q1 2026

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
075150225300375450525600Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Income YoY Variation (%)

Operating Income YoY VariationNet Income YoY Variation
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
-80-70-60-50-40-29-19-91Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Breakdown

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
08M15M22M30M38M45M52M60MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
💰 Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueStock Based Compensation To Revenue
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Free Cash Flow

Cash Flow to Debt Ratio

Cash At End Of Period
025M50M75M100M125M150M175M200MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
🏦 Balance Sheet
📈 Key Metrics